Angiotensin III (human, mouse)
(Synonyms: 血管紧张素III,Arg-Val-Tyr-Ile-His-Pro-Phe ) 目录号 : GP10110
An agonist at AT1 and AT2 receptors
Cas No.:13602-53-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Angiotensin III (Asp | Arg-Val-Tyr-Ile-His-Pro-Phe) is a hexapeptide formed as a result of a cleavage at the N-terminus of Angiotensin II, a key factor in the Renin-Angiotensin-Aldosterone (RAAS) system by angiotensinases located in red blood cells and the vascular beds of most tissues. It has 40% of the presser activity of angiotensin II, but 100% of the aldosterone-producing activity.
In peripheral Ang systems, Ang II is the main effector peptide in the systemic circulation, although exogenous Ang III can be as potent as Ang II in, for example, stimulating aldosterone secretion [1] or inhibiting renin release [2]. In the rat brain, Ang III was found to be equipotent with Ang II as a pressor agent or dipsogen [3] and was bound as avidly to the nervous system as Ang II. Ang receptor subtype AT1 has greater affinity towards Ang II and is also responsive to Ang III, while the AT2 receptor subtype appears to be more sensitive to Ang III but less responsive to Ang II [4].
References:
1. Blair-West, JR. et al. (1980) J. Endocrinol. 87, 409.
2. Fei, DTW. et al. (1980) Life Sci. 27, 1495.
3. Fink, GD. et al. (1985) Am. J. Physiol. Endocrinol. Metab. 249, E201.
4. Wright, JW. et al. (2011) Prog. Neurobiol. 95, 49.
| Cas No. | 13602-53-4 | SDF | |
| 别名 | 血管紧张素III,Arg-Val-Tyr-Ile-His-Pro-Phe | ||
| 化学名 | Angiotensin III (human, mouse) | ||
| Canonical SMILES | CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)N | ||
| 分子式 | C46H66N12O9 | 分子量 | 931.09 |
| 溶解度 | ≥ 93.1mg/mL in DMSO | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.074 mL | 5.3701 mL | 10.7401 mL |
| 5 mM | 0.2148 mL | 1.074 mL | 2.148 mL |
| 10 mM | 0.1074 mL | 0.537 mL | 1.074 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet